Client News

[at noodls] - - Conference call with investment community to follow at 8:30 a.m. ET - DUBLIN, Ohio--(BUSINESS WIRE)--Jul. 28, 2016-- Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) today announced that the Company ...
Posted: July 28, 2016, 2:38 pm
[Business Wire] - Navidea Biopharmaceuticals, Inc. today announced that the Company will report its financial results for the second quarter of 2016, on Thursday, August 4, 2016 prior to a conference call with the investment community scheduled at 8:30 a.m.
Posted: July 28, 2016, 2:15 pm
[at noodls] - TEL AVIV, Israel, July 28, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
Posted: July 28, 2016, 12:28 pm
[PR Newswire] - Co., Ltd. ("Samil") today announced the execution of a license agreement (the "Agreement") for an exclusive, royalty-bearing license for the commercialization of Aramchol™ (with an option to manufacture) for the treatment of fatty liver indications including nonalcoholic steatohepatitis, or NASH, in the Republic of Korea, along (the "License"). Upon the signing of the Agreement, Samil will pay Galmed an up-front fee of approximately $2.0 million. Samil has also agreed to pay additional clinical- and regulatory-based milestone payments, which may aggregate to $6.0 million, as well as tiered, double-digit royalties payable on sales (under certain limitations). The funds provided by this Agreement will provide additional financing for Galmed's development programs. Additionally, following the ARREST Study, Samil has an option to extend the License to Vietnam, which, if exercised, would increase the clinical- and regulatory-based milestone payments.
Posted: July 28, 2016, 12:00 pm
[GlobeNewswire] - HORSHAM, Pa., July 28, 2016-- STRATA Skin Sciences, Inc., a medical technology company dedicated to developing and commercializing innovative products for the diagnosis and treatment of serious dermatological ...
Posted: July 28, 2016, 12:00 pm
[at noodls] - REDWOOD CITY, Calif., July 28, 2016 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ:CDXS), a leading protein engineering company, announces the successful completion of its obligations under a collaborative ...
Posted: July 28, 2016, 11:08 am
[GlobeNewswire] - REDWOOD CITY, Calif., July 28, 2016-- Codexis, Inc., a leading protein engineering company, announces the successful completion of its obligations under a collaborative research and development agreement ...
Posted: July 28, 2016, 11:00 am
[at noodls] - TEL AVIV, Israel, July 27, 2016/PRNewswire / -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ('Galmed' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of a once-daily, ...
Posted: July 27, 2016, 12:48 pm
[PR Newswire] - TEL AVIV, Israel, July 27, 2016 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development ...
Posted: July 27, 2016, 12:30 pm
[at noodls] - WALTHAM, Mass., July 27, 2016 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report second quarter 2016 financial results on Thursday, August 4, 2016. The ...
Posted: July 27, 2016, 12:08 pm
[at noodls] - Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDA Pluristem has already ...
Posted: July 27, 2016, 11:38 am
[GlobeNewswire] - WALTHAM, Mass., July 27, 2016-- Repligen Corporation today announced that the Company will report second quarter 2016 financial results on Thursday, August 4, 2016. The Company will issue a press release ...
Posted: July 27, 2016, 11:30 am
[GlobeNewswire] - Clinical Advisory Board of leading orthopedic specialists and experts in rehabilitation met to discuss the design of the Phase III study prior to submission of the protocol to the FDA Pluristem has already ...
Posted: July 27, 2016, 11:00 am
[at noodls] - 8025bb44-f261-4814-9f93-1db4a3149490.pdf NEWS RELEASE AURINIA ESTABLISHES AT-THE-MARKET FACILITY Victoria, British Columbia - July 22, 2016: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) ("Aurinia" ...
Posted: July 22, 2016, 10:08 pm
[Business Wire] - Aurinia Pharmaceuticals Inc. today announced that it has entered into a Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co.
Posted: July 22, 2016, 9:18 pm